BLA 208751 · Novo
Fiasp Penfill
Insulin Aspart · Subcutaneous, Intravenous, Subcutaneous · Insulin Analog
Last checked: Nov 19, 2026Latest source record: Jun 21, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Sep 29, 2017
Approved uses
4
Original approval plus efficacy supplements
Registered trials
485
129 Phase 3, 9 recruiting
FAERS reports
12,548
10,461 serious, 1,455 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 21, 2023.
FIASP is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. • FIASP is a rapid-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus ( 1 ).
Mechanism: The primary activity of FIASP is the regulation of glucose metabolism. Insulins, including insulin aspart, the active ingredient in FIASP, exert their specific action through binding to insulin receptors. Receptor-bound insulin lowers blood glucose by facilitating cellular uptake of glucose into skeletal muscle and adipose tissue and by inhibiting the output of glucose from the liver. Insulin inhibits lipolysis in the adipocyte, inhibits proteolysis, and enhances protein synthesis.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 19, 2019 Supplement 10 · Efficacy LetterLabelPediatric CDTL Review
- Dec 19, 2019 Supplement 11 · Efficacy LetterLabelReview
- Oct 21, 2019 Supplement 8 · Efficacy LabelLetter
- Sep 29, 2017 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
3 products under this application
- FIASP PENFILL · INSULIN ASPART 300 UNITS/3ML (100 UNITS/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- FIASP · INSULIN ASPART 1000 UNITS/10ML (100 UNITS/ML) · SOLUTION, INTRAVENOUS, SUBCUTANEOUS · Prescription
- FIASP FLEXTOUCH · INSULIN ASPART 300 UNITS/3ML (100 UNITS/ML) · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Insulin Aspart" as an intervention, any sponsor and status, largest first.
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) StudyPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT00101751 · 4,877 participants · Start Oct 2004 · Primary completion Jun 2006
Drug: biphasic insulin aspart · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Princeton, New Jersey
- A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03689374 · 2,274 participants · Start Oct 1, 2018 · Primary completion Feb 22, 2021
Drug: Semaglutide; Insulin aspart and 1 more · For: Diabetes Mellitus, Type 2
Sites: Banja Luka, Bosnia and Herzegovina; Sarajevo, Bosnia and Herzegovina; Tuzla, Bosnia and Herzegovina · 210 sites in all
- DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational DiabetesPivotal-lookingRecruiting
Ohio State UniversityAcademic, hospital or other
NCT06445946 · 1,572 participants (planned) · Start Aug 1, 2024 · Primary completion Dec 2029
Drug: Metformin; Insulin · For: Gestational Diabetes Mellitus; Pregnancy, High Risk
Sites: Tuscaloosa, Alabama; Los Angeles, California; San Francisco, California · 26 sites in all
- Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT01831765 · 1,290 participants · Start Aug 26, 2013 · Primary completion May 12, 2015
Drug: Faster-acting insulin aspart; insulin detemir and 2 more · For: Diabetes; Diabetes Mellitus, Type 1
Sites: Mobile, Alabama; Tucson, Arizona; Anaheim, California · 191 sites in all
- Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03268005 · 1,264 participants · Start Sep 19, 2017 · Primary completion Jan 7, 2019
Drug: Faster-acting insulin aspart; Insulin aspart and 2 more · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Concord, California; Fresno, California; Fullerton, California · 167 sites in all
- Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT02500706 · 1,108 participants · Start May 4, 2016 · Primary completion Jul 17, 2017
Drug: Faster-acting insulin aspart; insulin aspart and 1 more · For: Diabetes; Diabetes Mellitus, Type 1
Sites: Tucson, Arizona; Concord, California; Encino, California · 152 sites in all
- Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT00972283 · 1,006 participants · Start Sep 1, 2009 · Primary completion Oct 28, 2010
Drug: insulin degludec; insulin glargine and 1 more · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Alexander City, Alabama; Birmingham, Alabama; Goodyear, Arizona · 136 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- blood glucose increased1,093
- nausea814
- dyspnoea754
- hypoglycaemia743
- vomiting717
- off label use711
- drug ineffective643
- abdominal pain542
- diarrhoea525
- condition aggravated522
- fatigue516
- acute kidney injury466
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 35 |
| 2005 | 30 |
| 2006 | 35 |
| 2007 | 65 |
| 2008 | 110 |
| 2009 | 137 |
| 2010 | 111 |
| 2011 | 97 |
| 2012 | 146 |
| 2013 | 193 |
| 2014 | 238 |
| 2015 | 311 |
| 2016 | 353 |
| 2017 | 384 |
| 2018 | 711 |
| 2019 | 769 |
| 2020 | 893 |
| 2021 | 1,227 |
| 2022 | 1,291 |
| 2023 | 1,222 |
| 2024 | 1,406 |
| 2025 | 1,610 |
| 2026 | 1,174 |
Recalls
3 FDA enforcement reports for this application.
Mar 22, 2021 · Class I · Terminated
Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.
Mar 22, 2021 · Class I · Terminated
Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.
Mar 22, 2021 · Class I · Terminated
Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Fiasp (Insulin Aspart (Niacinamide))
2024 spending
$64.1M
Beneficiaries
26,825
83,323 claims
Per beneficiary
$2,389
$27.79 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $8,960,478 |
| 2021 | $11,997,955 |
| 2022 | $16,947,897 |
| 2023 | $23,960,286 |
| 2024 | $64,072,644 |
Part D: Fiasp Flextouch (Insulin Aspart (Niacinamide))
2024 spending
$289M
Beneficiaries
131,189
398,663 claims
Per beneficiary
$2,207
$35.44 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $29,337,196 |
| 2021 | $45,295,952 |
| 2022 | $68,499,735 |
| 2023 | $105,895,817 |
| 2024 | $289,492,211 |
Part D: Fiasp Penfill (Insulin Aspart (Niacinamide))
2024 spending
$4.9M
Beneficiaries
2,286
5,790 claims
Per beneficiary
$2,156
$33.98 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $345,965 |
| 2021 | $790,134 |
| 2022 | $1,263,555 |
| 2023 | $1,637,027 |
| 2024 | $4,929,500 |
Part B: Fiasp* (Insulin Aspart (Niacinamide)*) · HCPCS J1811
2024 spending
$1.8M
Beneficiaries
1,562
4,313 claims
Per beneficiary
$1,123
2024 ASP limit $7.33 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $711,365 |
| 2024 | $1,754,312 |
Part B: Fiasp Penfill* (Insulin Aspart (Niacinamide)*) · HCPCS J1817
2024 spending
$55.5M
Beneficiaries
35,179
145,231 claims
Per beneficiary
$1,577
2024 ASP limit $5.12 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $161,240,121 |
| 2021 | $156,744,156 |
| 2022 | $127,065,578 |
| 2023 | $106,195,555 |
| 2024 | $55,491,178 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial.
Mathieu C, Ásbjörnsdóttir B, Bajaj HS, et al. · Lancet 2023 · Randomized Controlled Trial, Multicenter Study
- Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial.
Russell-Jones D, Babazono T, Cailleteau R, et al. · Lancet 2023 · Clinical Trial, Phase III, Randomized Controlled Trial
- Biosimilars and Novel Insulins.
Ampudia-Blasco FJ · Am J Ther 2020 · Systematic Review
- Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial.
Billings LK, Andreozzi F, Frederiksen M, et al. · Lancet Diabetes Endocrinol 2025 · Randomized Controlled Trial, Multicenter Study
- Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 1 diabetes.
Hövelmann U, Engberg S, Heise T, et al. · Diabetes Obes Metab 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an openߛlabel, multinational, randomised, controlled, non-inferiority trial.
Mathiesen ER, Alibegovic AC, Corcoy R, et al. · Lancet Diabetes Endocrinol 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Novo · Also marketed as Fiasp, Fiasp Flextouch
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.